Neuren’s shares double on stunning drug trial results
Tom RichardsonJournalist
ASX-listed biotech Neuren Pharmaceuticals is close to a massive cash windfall after its US partner Acadia reported stunning clinical trial results for Neuren’s trofinetide drug to treat the neurological disorder Rett syndrome in early childhood.
Neuren CEO John Pilcher is very confident the drug will get FDA approval by the end of 2022 or early 2023.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Equity markets
Fetching latest articles